Emergence of Panton-Valentine Leukocidin-Positive ST80 Clone of Community-Associated Methicillin-Resistant Staphylococcus aureus in Busan, Korea.
10.4167/jbv.2016.46.4.269
- Author:
So Hae PARK
1
;
Soo Myung HWANG
Author Information
1. Department of Clinical Laboratory Science, Catholic University of Pusan, Busan, Korea. smhwang@cup.ac.kr
- Publication Type:Brief Communication
- Keywords:
MRSA;
ST80 clone;
Multilocus sequence type;
Staphylocoagulase type
- MeSH:
Anti-Bacterial Agents;
Busan*;
Clone Cells*;
Coagulase;
Delivery of Health Care;
Ear;
Europe;
Fusidic Acid;
Korea*;
Leukocidins;
Methicillin Resistance*;
Methicillin-Resistant Staphylococcus aureus*;
Middle East;
Multilocus Sequence Typing;
Staphylococcal Protein A;
Staphylococcus aureus;
Tetracycline;
Virulence
- From:Journal of Bacteriology and Virology
2016;46(4):269-274
- CountryRepublic of Korea
- Language:English
-
Abstract:
Community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) has become widespread in the community and healthcare settings, and a number of clonal lineages emerged on every country. Sequence type (ST) 80 clone of CA-MRSA was dominant in Europe and has increasingly been isolated from the Middle East but so far never found in Korea. In this study, 48 MRSA isolates recovered from ear infections were characterized by multilocus sequence typing (MLST), staphylococcal cassette chromosome mec (SCCmec) typing, staphylocoagulase (SC) genotyping, staphylococcal protein A gene (spa) typing, accessory gene regulator (agr) typing, and virulence gene profiling. Most MRSA strains belonged to three major clones: ST5-SCCmec II-SC type II (n=19, 39.6%), ST239-SCCmec III-SC type IV (n=15, 31.2%), and ST72-SCCmec IV-SC type Vb (n=11, 22.9%). Among the isolates, one strain was Panton- Valentine leukocidin (PVL)-positive ST80-SCCmec IV-SC type XIa - spa type t044-agr group III, and exfoliative toxin D-positive. This strain was susceptible to most antibiotics, but resistant to tetracycline and fusidic acid. This is the first report on the emergence of European ST80 CA-MRSA clone in Korea.
